View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. B Medical Systems
9 August 2022

Azenta Announces Agreement to Acquire B Medical Systems

Azenta (Nasdaq: AZTA) today announced that it has entered into a definitive agreement to acquire B Medical Systems and its subsidiaries (“B Medical”), a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments across the globe. The cash purchase price to be paid at closing will be approximately €410m. Additional cash consideration, up to €50m, may be paid upon achievement of certain future performance milestones. The transaction is expected to close in October 2022.

B Medical is headquartered in Hosingen, Luxembourg, and is one of the leading vaccine cold chain providers serving primarily fast-growing emerging markets, which require secure and reliable temperature-controlled storage and transport solutions. The portfolio includes vaccine transport systems with real-time monitoring solutions, medical refrigeration for ambient to -86°C temperatures, and blood management solutions. B Medical has an installed base of more than 500,000 units spanning approximately 150 countries across the globe. The Luxembourg headquarters includes a state-of-the-art, highly automated manufacturing facility.

This acquisition complements Azenta’s cold chain capabilities, adding differentiated solutions for reliable and traceable transport of temperature-sensitive specimens. “We are excited to add B Medical into our growing portfolio of offerings,” said Steve Schwartz, President and CEO of Azenta. “B Medical has done an outstanding job carving out a strong market position in the vaccine cold chain, and we see a breadth of opportunities to drive even further value from the portfolio by leveraging the Azenta platform.”

B Medical CEO, Luc Provost, who has been with the company for over 20 years, and Jesal Doshi, Deputy CEO since 2015, are expected to join Azenta and continue to lead the business. Mr Provost commented, “We are excited to join the Azenta team as we combine our capabilities and expertise in cold chain solutions to drive the next leg of growth. Together, I look forward to continuing our mission to create technology that helps save lives across the world.”

Click here to read the full press release from Azenta

Click here to read the full press release from Navis Capital Partners

Every year, millions of biospecimens, including human tissues and blood, are preserved around the world for disease diagnosis and research.
The use of tumor markers to diagnose, assess prognosis, and select a suitable cancer treatment has become possible due to the development of inexpensive and...
Many cell and gene therapy solutions have shown considerable promise as a source of possible treatments for a wide range of chronic disorders.
The reliability of an ultra-low freezer (ULT) is dependent on its ability to maintain the temperature-sensitive specimens it needs to store at their intended temperature.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology